Category Archives: Liver-brain Axis

A pilot study of Golexanolone, a new GABA-A receptor modulating steroid antagonist, in patients with covert hepatic encephalopathy

Montagnese S, Lauridsen M, Vilstrup H, Zarantonello L, Lakner G, Fitilev S, Zupanets I, Kozlova I, Bunkova E, Tomasiewicz K, Berglund JE, Rorsman F, Hagström H, Kechagias S, Ocklind CE, Mauney J, Thunarf F, Mokhatarani M, Bäckström T, Doverskog M, Lins LE, Månsson M, Samuelson P, Nilsson D, Schalling M, Johansson M, Arlander E, Scharschmidt […]

Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues

Montagnese S, Bajaj JS Drugs Hepatic encephalopathy (HE) has a major impact on health-related quality of life (HRQOL) in patients, which has clinical and psychosocial consequences. HRQOL in cirrhosis has been measured by generic and liver-specific instruments, with most studies indicating a negative impact of HE. HRQOL abnormalities span daily functioning, sleep–wake cycle changes, and […]

Clinical value of asterixis in 374 well-characterised patients with cirrhosis and varying degree of hepatic encephalopathy

Formentin C, Zarantonello L, Mangini C, Angeli P, Merkel C, Montagnese S Digestive and Liver Disease Current guidelines for the diagnosis of hepatic encephalopathy (HE) include the clinical sign asterixis, which defines grade II overt HE in the absence of disorientation to time [ 1 ]. Asterixis has also been used as an outcome in clinical trials […]

A meta-analysis of magnetic resonance spectroscopy in the diagnosis of hepatic encephalopathy

Zeng G, Penninkilampi R, Chaganti J, Montagnese S, Brew BJ, Danta M Neurology Objective Various imaging modalities have been used to explore pathogenic mechanisms and stratify the severity of hepatic encephalopathy (HE). The hypothesis of this meta-analysis was that there is a progressive identifiable derangement of imaging measures using magnetic resonance spectroscopy (MRS) related to the […]

Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy

Senzolo M, Zarantonello L, Formentin C, Orlando C, Beltrame F, Vuerich A, Angeli P, Burra P, Montagnese S Metabolic Brain Disease Hepatic encephalopathy (HE) occurs in 20–50% of patients after transjugular intrahepatic portosystemic shunt (TIPS) placement. Older age, HE history and severe liver failure have all been associated with post-TIPS HE but it remains difficult to […]